2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors
SUZHOU, China, Sept. 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today released the preliminary data from the Phase I bridging study of the Company's investigational anti-PD-1 monoclonal antibody CS1003 for the first time, in an oral presentation at the...
2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%
SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced trial data from the esophageal squamous cell carcinoma (ESCC) cohort of a Phase Ib clinical trial of the Company's investigational anti-PD-L1 antibody CS1001 in an oral pre...
CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST
SUZHOU, China, Aug. 26, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient inChina has been dosed in the Phase I/II bridging study of avapritinib, which was discovered by CStone's partner Blueprint Medicines. This stand-alone registrational b...
CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting
SUZHOU, China, Aug. 23, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO, 2019 CSCO Annual Meeting) has accepted three abstracts on the clinical trials of CS1001 (Anti...
CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study
SUZHOU, China, Aug. 23, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received ethics approval from the Human Research Ethics Committee inAustralia for the Phase I clinical trial of CS3002, andAustralia's Therape...
CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting
SUZHOU, China, Aug. 20, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that an abstract on the company's CS1001-201 trial has been submitted to the upcoming 2019 American Society of Hematology (ASH) Annual Meeting. This will mark the first release of CS1001-201...
Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress
SUZHOU, China, Aug. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that an abstract on the company's ongoing CS1001-101 Phase Ib clinical study has been accepted for poster presentation at the upcoming European Society for Medical Oncology (ESMO) 2019 Annua...
CStone Pharmaceuticals Reports First Half 2019 Financial Results
SHANGHAI, Aug. 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and molecularly-targeted drugs for the treatment of cancer, today released its recent business ...
CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study
SUZHOU, China, Aug. 13, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announces the dosing of the first patient inChina for the Phase I registrational study of BLU-667, which was discovered by the company's partner Blueprint Medicines. This clinical trial is a part of t...
CStone to Build Global R&D Headquarters and Industrialization Base in the Suzhou Industrial Park
SUZHOU, China, Aug. 7, 2019 /PRNewswire/ -- The signing ceremony for CStone Pharmaceuticals' ("CStone") (HKEX: 2616) Global R&D Headquarters and Industrialization Base ("the Project") took place in Suzhouon August 6. The event marks the building of yet another state-of-the-art research and devel...
CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML
SUZHOU, China, July 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) announced today that it has received approval from China National Medical Products Administration (NMPA) to initiate a Phase I bridging registrational study of ivosidenib (TIBSOVO) for the treatment of rela...
CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST
SUZHOU, China, July 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient has been dosed inChina with avapritinib in the ongoing global Phase III VOYAGER clinical trial. This study is designed to evaluate the safety and efficacy of avapritini...
CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib
SUZHOU, China, June 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced that the company has entered into a global clinical collaboration withChina focus with Bayer HealthCare LLC to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity ...
CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC
SUZHOU, China, June 5, 2019 /PRNewswire/ -- CStone Pharmaceuticals (CStone; HKEX: 2616) announced that it has received approval to initiate clinical development inChina of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). T...
CStone submits new drug application for TIBSOVO(R) in Taiwan for the treatment of relapsed/refractory AML
HONG KONG, June 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced that a new drug application (NDA) for TIBSOVO® (ivosidenib) has been submitted by a third-party to the Taiwan Food and Drug Administration (TFDA) as the first to-be-approved treatment of adult patients...
Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint
SUZHOU, China, May 23, 2019 /PRNewswire/ -- The partner of CStone Pharmaceuticals ("Cstone"; HKEX:2616), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) ("Agios") announced that the global Phase 3 ClarIDHy trial of TIBSOVO (ivosidenib) in previously treated cholangiocarcinoma patients with an isocitr...
CStone and Numab announce exclusive regional licensing agreement for ND021, a multi-functional drug candidate and potential next-generation immunotherapy
SUZHOU, China and ZURICH, May 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") today announce that they have entered into an exclusive regional licensing agreement for the development and commercialization of ND021, a potential best-in-clas...
First patient dosed in Phase III GEMSTONE-303 study for CS1001 in combination with chemotherapy in first-line gastric adenocarcinoma and gastro-esophageal junction adenocarcinoma
SHANGHAI, April 16, 2019 /PRNewswire/ -- CStone Pharmaceuticals (the "Company" or "CStone"; HKEX: 2616) announces that the first patient has been successfully enrolled and dosed in a Phase III clinical trial assessing CS1001,China's first fully human, full-length anti-PD-L1 antibody, in combinati...
CStone received IND approval in China for avapritinib Phase I/II bridging registrational study in patients with advanced gastrointestinal stromal tumors
SHANGHAI, April 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) announced today that the National Medical Products Administration (NMPA) recently approved the initiation of a Phase I/II clinical trial inChina evaluating avapritinib, a drug candidate discovered by the compan...
CStone Pharmaceuticals presented poster of pre-clinical result for CS1003 at AACR
SHANGHAI, April 4, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX:2616) delivered a poster of pre-clinical data of CS1003 at the 2019 American Association for Cancer Research (AACR) Annual Meeting. CS1003 is a humanized IgG4 PD-1 monoclonal antibody designed to block the interaction...
